Submit a Letter to the Editor for:

Essential role of sphingosine 1–phosphate receptor 2 in pathological angiogenesis of the mouse retina

Athanasia Skoura, Teresa Sanchez, Kevin Claffey, Suzanne M. Mandala, Richard L. Proia, Timothy Hla

Published in Volume 117, Issue 9

J Clin Invest. 2007; 117(9):2506 doi:10.1172/JCI31123

Abstract | Full text | PDF | Supplemental material

S phingosine 1–phosphate (S1P), a multifunctional lipid mediator that signals via the S1P family of G protein–coupled receptors (S1PR), regulates vascular maturation, permeability, and angiogenesis. In this study, we explored the role of S1P 2 receptor (S1P₂R) in normal vascularization and hypoxia-triggered pathological angiogenesis of the mouse retina. S1P₂R is strongly induced in ECs during hypoxic stress. When neonatal mice were subjected to ischemia-driven retinopathy, pathologic neovascularization in the vitreous chamber was suppressed in S1p2^–/– mice concomitant with reduction in endothelial gaps and inflammatory cell infiltration. In addition, EC patterning and normal revascularization into the avascular zones of the retina were augmented. Reduced expression of the proinflammatory enzyme cyclooxygenase-2 (COX-2) and increased expression of eNOS were observed in the S1p2^–/– mouse retina. S1P₂R activation in ECs induced COX-2 expression and suppressed the expression of eNOS. These data identify the S1P₂R-driven inflammatory process as an important molecular event in pathological retinal angiogenesis. We propose that antagonism of the S1P₂R may be a novel therapeutic approach for the prevention and/or treatment of pathologic ocular neovascularization.

Guidelines: The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered. Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.